NCT06872892 is a Phase 3 clinical trial of BI 1291583 in Bronchiectasis, sponsored by Boehringer Ingelheim.

Who is sponsoring NCT06872892?

NCT06872892 is sponsored by Boehringer Ingelheim.

What drugs are being tested in NCT06872892?

Interventions in NCT06872892: BI 1291583, Placebo matching BI 1291583.

What condition does NCT06872892 study?

NCT06872892 studies Bronchiectasis.

Is NCT06872892 still recruiting?

NCT06872892 is currently recruiting now. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT06872892

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

Recruiting now Phase 3 Last updated 15 April 2026

What this trial tests

Phase 3 trial testing BI 1291583 in Bronchiectasis in 1,755 participants. Currently enrolling.

Timeline

9 June 2025

Primary endpoint
14 September 2028

12 October 2028

Quick facts

Lead sponsor	Boehringer Ingelheim
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	1,755
Start date	9 June 2025
Primary completion	14 September 2028
Estimated completion	12 October 2028
Sites	495 locations across Hong Kong, Italy, Finland, Japan, Malaysia, Kazakhstan, Taiwan, Ireland

Drugs / interventions tested

BI 1291583 — full drug profile →
Placebo matching BI 1291583 — full drug profile →

Conditions studied

Bronchiectasis — all drugs for Bronchiectasis →

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

12 and older, any sex, with Bronchiectasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medicine. Participants take 1 tablet once a day for up to 1 year and 6 months. Participants are in the study for up to 1 year and 8 months. During this time, participants visit the study site up to 10 times and get about 13 phone calls from the site staff. Participants regularly complete a diary on a smartphone about their bronchiectasis symptoms and study doctors regularly check for any changes. The study doctors document when participants experience flare-ups. The number of flare-ups is compared between the participants who receive BI 1291583 and those who receive the placebo. The study doctors also regularly check participants' health and take note of any unwanted effects.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Tackling Neutrophilic Inflammation in Bronchiectasis: From Macrolides to Cathepsin C Inhibitors.
Gramegna A, Premuda C, Putti G, Piedepalumbo FV, et al · · 2026 · PMID 41993889 · DOI 10.2147/jir.s558745
Bronchiectasis Treatment Goals, Unmet Needs, and Emerging Therapies: A Podcast.
Flume PA, Maselli DJ. · · 2026 · PMID 41269659 · DOI 10.1007/s41030-025-00330-1
Breaking boundaries or a small piece of the puzzle: can CFTR modulators transform bronchiectasis care?
Graeber SY, Frost F. · · 2025 · PMID 41189579 · DOI 10.1183/23120541.00593-2025
Dipeptidyl peptidase 1 inhibitors for inflammatory respiratory diseases: mechanisms, clinical trials, and therapeutic prospects.
Zhang D, Zhang W, Hu P, Zhang W. · · 2025 · PMID 40918524 · DOI 10.3389/fphar.2025.1656316

Verify or expand the search:

Other trials of BI 1291583

Trials testing the same drug.

NCT07023354 — A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems · Phase 1 · recruiting
NCT06917872 — A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood · Phase 1 · completed
NCT06791187 — A Study in Healthy People to Test Whether BI 1291583 Influences the Amount of Dabigatran in the Body · Phase 1 · completed
NCT06631417 — A Study in Healthy People to Test How 2 Different Doses of BI 1291583 Are Taken up in the Body When Given in 3 Different · Phase 1 · completed
NCT05865886 — A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™) · Phase 2 · completed

Other recruiting trials for Bronchiectasis

Currently open trials in the same condition.

NCT07283497 — Itraconazole Therapy In Bronchiectasis With Airway Mold · Phase 4 · recruiting
NCT07188675 — Functional Inspiratory Training in Bronchiectasis · NA · recruiting
NCT06897761 — Development of an Interactive Digital Respiratory Game and Device and Investigation of Its Effectiveness in Children Wit · NA · recruiting
NCT07147803 — Sleep Quality in Patients With Non-cystic Fibrosis Bronchiectasis · active not recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting

Other Boehringer Ingelheim trials

Trials by the same sponsor.

NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection · not yet recruiting
NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a · not yet recruiting
NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I · Phase 3 · not yet recruiting
NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants · Phase 1 · not yet recruiting
NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06872892 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06872892.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing